Idiopathic pulmonary fibrosis

  • Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease with a poor prognosis, with a 5-year survival rate of less than 50% and a 10-year survival rate of 15% after diagnosis. By 2015, 200,000 cases were reported in the United States alone and 5 million cases worldwide, and the incidence rate is also increasing

  • A therapeutic agent for idiopathic pulmonary fibrosis has not been developed so far, and è the currently available therapies can only delay progression of the disease. There is no way to lower the mortality rate except through lung transplantation for patients under the age of 65 who don't have underlying diseases.

  • Intencell® is expected to be the only therapeutic agent for idiopathic pulmonary fibrosis as it has excellent anti-inflammatory effects and is expected to be effective in the regeneration of fibrotic tissues.